Scavenger Receptors and Their Potential as Therapeutic Targets in the Treatment of Cardiovascular Disease

Table 3

List of the main viral gene therapy experiments examining the therapeutic potential of scavenger receptors.

SR used/targeted	Vector used	Outcome	References
LOX-1	FG AdV	Inhibition of the progression of atherosclerosis	Ishigaki et al. [263]
Soluble SR-A1	FG AdV	Foam cell formation inhibited	Laukkanen et al. [265]
Soluble SR-A1	FG AdV	Abrogation of the atherosclerotic lesion area	Jalkanen et al. [266]
Soluble SR-A1	AAV	Abrogation of the atherosclerotic lesion area	Jalkanen et al. [267]
SR-B1	FG AdV	Reduction of plasma HDL	Kozarsky et al. [54]
SR-B1	FG AdV	Reduction of plasma HDL	Kozarsky et al. [55]
SR-B1	FG AdV	Reduction of plasma HDL, increase of LDL	Tancevski et al. [268]
SR-B1	FG AdV	Increased biliary secretion of cholesterol	Wiersma et al. [269]
SR-B1 and Apobec 1	HC-AdV	Reduction of Apo B levels, elevation of NO	Zhong et al. [270]
SR-B1/CD36	FG AdV	SR-B1 mediated uptake of cholesterol esters higher than that by CD36. However, CD36 resulted in higher levels of Ox-LDL degradation	de Villiers et al. [271] and Sun et al. [272]
CD36	FG AdV	Increased hepatic fatty acid uptake	Koonen et al. [273]
SR-PSOX	LV	Decreased foam cell formation	Zhang et al. [120]

SR: scavenger receptor, FG AdV: first-generation adenoviral vector, AAV: adeno-associated viral vector, HC-AdV: high capacity adenoviral vector, LV: lentiviral vector, SR-A: scavenger receptor class A, LOX-1: lectin-like oxidised low density lipoprotein receptor-1, SR-B1: scavenger receptor class B 1, SR-PSOX: scavenger receptor that binds to phosphatidylserine and oxidized lipoprotein, Apobec 1: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 1, CD36: cluster of differentiation 36, LDL: low density lipoprotein, HDL: high density lipoprotein, and NO: nitric oxide.